BACKGROUND: The local peritoneal effects of low-glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF) have been extensively described. However, the systemic effects of prolonged prescription of these solutions are unknown. This study aimed to evaluate the effects of neutral pH and low-GDP PDF on systemic inflammation and endothelial dysfunction markers in peritoneal dialysis (PD) patients. METHODS: This is a multicenter, open labeled, randomized controlled trial including one hundred fifty-two patients initiating continuous ambulatory peritoneal dialysis for end-stage renal disease from seven centers in Korea. Participants were randomly allocated to conventional PDF (Stay safe®; Fresenius Medical Care, Bad Homburg, Germany) or low-GDP PDF (Balance®; Fresenius Medical Care) and were followed for 1 year. Primary outcome variable was the inflammation and endothelial dysfunction index (IEDI), a composite score derived from serum levels of soluble intercellular adhesion molecule (sICAM)-1, soluble vascular cellular adhesion molecule (sVCAM)-1 and high-sensitivity C-reactive protein (hs-CRP). sICAM-1, sVCAM-1, residual renal function (RRF), peritoneal membrane transport characteristics, ultrafiltration volume and nutritional parameters were measured as secondary outcome variables. RESULTS: Of 152 patients randomized, 146 (low-GDP: conventional PDF, 79:67) patients entered the trial (46% male, 53% with diabetes mellitus). At 12-month follow-up, the low-GDP group had significantly lower levels of IEDI, sICAM-1 and sVCAM-1 compared to the conventional group; hs-CRP was not different between groups. Peritoneal transport characteristics, RRF, nutritional parameters, incidence of peritonitis and death-censored technique survival were not different between groups. CONCLUSION:Neutral pH and low-GDP PDF likely produce fewer changes in markers of endothelial dysfunction compared to conventional PDF in incident PD patients.
RCT Entities:
BACKGROUND: The local peritoneal effects of low-glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF) have been extensively described. However, the systemic effects of prolonged prescription of these solutions are unknown. This study aimed to evaluate the effects of neutral pH and low-GDP PDF on systemic inflammation and endothelial dysfunction markers in peritoneal dialysis (PD) patients. METHODS: This is a multicenter, open labeled, randomized controlled trial including one hundred fifty-two patients initiating continuous ambulatory peritoneal dialysis for end-stage renal disease from seven centers in Korea. Participants were randomly allocated to conventional PDF (Stay safe®; Fresenius Medical Care, Bad Homburg, Germany) or low-GDP PDF (Balance®; Fresenius Medical Care) and were followed for 1 year. Primary outcome variable was the inflammation and endothelial dysfunction index (IEDI), a composite score derived from serum levels of soluble intercellular adhesion molecule (sICAM)-1, soluble vascular cellular adhesion molecule (sVCAM)-1 and high-sensitivity C-reactive protein (hs-CRP). sICAM-1, sVCAM-1, residual renal function (RRF), peritoneal membrane transport characteristics, ultrafiltration volume and nutritional parameters were measured as secondary outcome variables. RESULTS: Of 152 patients randomized, 146 (low-GDP: conventional PDF, 79:67) patients entered the trial (46% male, 53% with diabetes mellitus). At 12-month follow-up, the low-GDP group had significantly lower levels of IEDI, sICAM-1 and sVCAM-1 compared to the conventional group; hs-CRP was not different between groups. Peritoneal transport characteristics, RRF, nutritional parameters, incidence of peritonitis and death-censored technique survival were not different between groups. CONCLUSION: Neutral pH and low-GDP PDF likely produce fewer changes in markers of endothelial dysfunction compared to conventional PDF in incident PDpatients.
Authors: Seychelle Yohanna; Ali M A Alkatheeri; Scott K Brimble; Brendan McCormick; Arthur Iansavitchous; Peter G Blake; Arsh K Jain Journal: Clin J Am Soc Nephrol Date: 2015-06-05 Impact factor: 8.237
Authors: M Miler; N Nikolac; D Segulja; S Kackov Maslac; I Celap; K Altabas; S Sefer; A M Simundic Journal: J Endocrinol Invest Date: 2016-09-06 Impact factor: 4.256
Authors: Maria Bartosova; Betti Schaefer; Justo Lorenzo Bermejo; Silvia Tarantino; Felix Lasitschka; Stephan Macher-Goeppinger; Peter Sinn; Bradley A Warady; Ariane Zaloszyc; Katja Parapatics; Peter Májek; Keiryn L Bennett; Jun Oh; Christoph Aufricht; Franz Schaefer; Klaus Kratochwill; Claus Peter Schmitt Journal: J Am Soc Nephrol Date: 2017-10-18 Impact factor: 10.121
Authors: April C E van Gennip; Natascha J H Broers; Karlien J Ter Meulen; Bernard Canaud; Maarten H L Christiaans; Tom Cornelis; Mariëlle A C J Gelens; Marc M H Hermans; Constantijn J A M Konings; Jeroen B van der Net; Frank M van der Sande; Casper G Schalkwijk; Frank Stifft; Joris J J M Wirtz; Jeroen P Kooman; Remy J H Martens Journal: PLoS One Date: 2019-09-13 Impact factor: 3.240
Authors: Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho Journal: Cochrane Database Syst Rev Date: 2018-10-26